Multicenter Performance Study of TriQuik Invitro Diagnostic Device

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-04-30

Study Completion Date

2023-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective and historical clinical study is designed to test the performance of the Genlantis TriQuik test kit (Cassette). The primary goal is to establish the sensitivity and specificity (i.e. how accurate the test is) when compared to the same patient's medical history.

Previous tests were performed on serum and whole blood specimens. A total of 607 serum specimens1 were collected for evaluation and comparison of the performance of the TriQuik Hepatitis B Surface Antigen (HBsAg) Test with a licensed commercial HBsAg EIA. 84 of 85 positive serum samples testing by the licensed commercial HBsAg EIA were reactive with TriQuik HBsAg Test and 520 of 522 negative samples testing by the licensed commercial HBsAg EIA were tested negative with TriQuik HBsAg Test.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

COVID-19 Immunity Assessment

NCT05080231

COVID-19

COMPLETED

TekiTrust Tests to Determine the Level of SARS-COV-2/COVID-19 Neutralizing Antibodies in the Blood

NCT05338762

SARS-CoV2 Infection

COMPLETED

Research & Evaluation of LumiraDx SARS-CoV-2 (COVID-19) Point of Care Ab Test

NCT04597047

Covid19

UNKNOWN NA

NOWDx Test for the Detection of Antibodies to COVID-19

NCT04690413

COVID-19 SARS-CoV-2 Coronavirus

COMPLETED NA

Evaluation of the LumiraDx Point of Care D-Dimer and CRP Tests

NCT04375982

Embolism and Thrombosis Infection Inflammation

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Objective To demonstrate clinical performance of the TriQuik Invitro Diagnostic device.

Measurement Methodology Whole blood samples are collected by fingerstick. Samples should be tested immediately.

Using the supplied sample dropper, transfer specimen blood drop into the sample well. Wait 20-30 seconds. Add two drops of the supplied assay buffer (\~90µL) to the same sample well Read result in 20 mins.

Primary end points will determine how accurate these tests are (p\<=0.02) by analyzing for:

Diagnostic Sensitivity; TP / (TP + FN) The ability of the test to correctly identify those patients with the disease Diagnostic Specificity; TN / (TN + FP) The ability of the test to correctly identify those patients who are truly free of the specific disease Positive Predictive Value: TP / (TP+ FP) The probability that subjects with a positive test truly have the disease. Negative Predictive Value: TN / (FN + TN) The probability that subjects with a negative test truly don't have the disease.

An estimated 200 patients are to be enrolled as follows:

150 with a documented medical history of HIV, HBV or HCV. A combination of 2 or 3 conditions is acceptable.

HbsAg patients need to have a HbsAg on file \< 2 years. HIV and HCV patients only need one antibody test in their medical chart.

50 with no documented medical history of HIV, HBV or HCV and are considered normal.

Male or female subjects, ages ≥18 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

To Demonstrate Clinical Performance of the TriQuik Invitro Diagnostic Device

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Positive test subjects

documented medical history of HIV, HBV or HCV. A combination of 2 or 3 conditions is acceptable.

TriQuik IVD

Intervention Type DIAGNOSTIC_TEST

TriQuik Invitro Diagnostic Device Cassettes. TriQuik Invitro Diagnostic Device Cassettes.

Control

no documented medical history of HIV, HBV or HCV and are considered normal.

TriQuik IVD

Intervention Type DIAGNOSTIC_TEST

TriQuik Invitro Diagnostic Device Cassettes. TriQuik Invitro Diagnostic Device Cassettes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TriQuik IVD

TriQuik Invitro Diagnostic Device Cassettes. TriQuik Invitro Diagnostic Device Cassettes.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* a documented medical history of HIV, HBV or HCV. A combination of 2 or 3 conditions is acceptable.

* HbsAg patients need to have a HbsAg on file \< 2 years.
* HIV and HCV patients only need one antibody test in their medical chart.
* no documented medical history of HIV, HBV or HCV and are considered normal.
* Male or female subjects, ages ≥18 years.
* Signed informed consent provided by an authorized subject representative (based on local Institutional Review Board (IRB)/ethics panel requirements).

Exclusion Criteria

Any other condition or prior therapy, which, in the opinion of the investigator, would make the subject unsuitable for this study.

Participation in any phase of another clinical research study involving the evaluation of another investigational drug or device within 30 days before randomization.

\-

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No